Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 455

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 455
---
 a subsequent reduction to 1% from April 1, 2022 until June 30, 2022). To offset the temporary suspension during the COVID -19pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. We expect that these initiatives, as well as other healthcare reform measures that may be adopted in the future, as well as the trend toward managed healthcare and increasing influence of managed care organizations, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government -fundedprograms may result in a similar reduction in payments from private payors. The implementation of current and future cost containment measures or other healthcare reforms may adversely affect our operations and prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. 259

MANAGEMENT OF PROFUSA Executive Officers and Directors Profusa is managed by its board of directors. Directors are elected by the shareholders of Profusa holding a majority of the issued and outstanding shares of stock in Profusa at an annual meeting of the shareholders and hold office until the their respective term expires after their election or until their successors are elected and qualified. A director may resign at any time and may be removed by the shareholders holding a majority of the issued and outstanding shares of stock entitled to vote in Profusa. Any vacancies on the Board of Directors may be filled by the unanimous vote of the remaining directors. A director elected to fill such vacancy will serve the unexpired term of his predecessor in office. The number of directors serving on the Board of Directors may be increased or decreased by the Board of Directors. The directors and executive officers as of the date of this proxy statement/prospectus are as follows:

| Name                    |     | Age |     | Position                                       |
| Executive Officers:     |     |     |     |                                                |
| Ben C. Hwang, Ph.D.     |     |  57 |     | Chairman of the Board; Chief Executive Officer |
| Non